Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Queensland Health
Covington
Mallinckrodt
US Army
Express Scripts
Moodys
Teva
McKinsey
Federal Trade Commission

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062752

« Back to Dashboard

NDA 062752 describes TETRACYCLINE HYDROCHLORIDE, which is a drug marketed by Abbott, Chartwell Tetra, Elkins Sinn, Ferrante, Heather, Hikma Pharms, Idt Australia Ltd, Impax Labs, Ivax Sub Teva Pharms, Mast Mm, Mylan, Purepac Pharm, Pvt Form, Roxane, Sun Pharm Industries, Superpharm, Valeant Pharm Intl, Warner Chilcott, Watson Labs, Wyeth Ayerst, Alpharma Us Pharms, and Proter, and is included in twenty-six NDAs. It is available from twelve suppliers. Additional details are available on the TETRACYCLINE HYDROCHLORIDE profile page.

The generic ingredient in TETRACYCLINE HYDROCHLORIDE is tetracycline hydrochloride. There are ninety-nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the tetracycline hydrochloride profile page.
Summary for 062752
Tradename:TETRACYCLINE HYDROCHLORIDE
Applicant:Chartwell Tetra
Ingredient:tetracycline hydrochloride
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 062752
Ingredient-typeTetracyclines
Suppliers and Packaging for NDA: 062752
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride CAPSULE;ORAL 062752 ANDA Alvogen Inc. 47781-508 N 47781-508-01
TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride CAPSULE;ORAL 062752 ANDA Alvogen Inc. 47781-509 N 47781-509-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength250MG
Approval Date:Aug 12, 1988TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength500MG
Approval Date:Aug 12, 1988TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
McKesson
Citi
Healthtrust
Julphar
Deloitte
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot